+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast to 2030- Product Image
Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674221
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Microbiome Therapeutics Market grew from USD 1.11 billion in 2024 to USD 1.27 billion in 2025. It is expected to continue growing at a CAGR of 14.65%, reaching USD 2.54 billion by 2030.

Unlocking the Promise of Microbiome Therapeutics

The advent of microbiome therapeutics represents a paradigm shift in modern medicine, harnessing the complex interactions between host and microbiota to prevent, manage, and potentially cure a wide array of diseases. This emerging class of interventions leverages targeted modulation of microbial communities to restore balance within the human body, offering a complementary or alternative pathway to conventional pharmacological approaches. As scientific understanding of the microbiome deepens, so too does the potential for innovative treatments that transcend traditional small-molecule or biologic therapies.

In this rapidly evolving landscape, stakeholders across the healthcare ecosystem-from academic researchers to biotech innovators and clinical practitioners-are converging to translate microbiome science into real-world solutions. This executive summary distills critical insights into the forces shaping the field, key drivers of adoption, and considerations for strategic positioning. By illuminating the foundational concepts and market dynamics, it provides decision-makers with a clear roadmap to navigate opportunities and challenges as the microbiome therapeutics sector matures.

Emerging Trends Reshaping the Microbiome Therapeutics Landscape

Recent breakthroughs in high-throughput sequencing, computational biology, and systems immunology have unlocked unprecedented clarity into the composition and function of microbial ecosystems. As analytical techniques become more affordable and precise, researchers can identify and characterize previously unrecognized microbial species, enzymes, and metabolic pathways that influence health and disease. This surge of data-driven insight has accelerated the discovery of live-biotherapeutic strains and defined consortia aimed at targeting specific pathophysiological processes.

Concurrently, regulatory agencies have begun to codify guidelines for the development, manufacturing, and quality control of microbiome-based products. Clearer pathways for clinical trials and standardized criteria for product characterization are reducing uncertainty and de-risking investment. On the commercial front, strategic collaborations between pharmaceutical incumbents, biotech startups, and academic institutions are streamlining translation from bench to bedside. These combined forces are propelling the sector toward a tipping point where microbiome therapeutics will move from niche applications to broader clinical adoption.

Assessing the Effects of US Tariffs on Microbiome Innovation

In early 2025, new tariff measures imposed by the United States on select biotech imports introduced an additional layer of complexity for manufacturers of microbiome therapeutics. These duties affect a range of critical inputs, including bioreactor components, specialized reagents, and certain proprietary delivery devices. As a result, production costs have been pressured upward, prompting supply chain reevaluation and strategic sourcing initiatives to mitigate exposure to increased levies.

Companies are responding by diversifying their supplier base, relocating aspects of manufacturing to tariff-exempt jurisdictions, and renegotiating long-term agreements to secure favorable terms. While these adjustments incur transitional expenses, they also catalyze supply chain resilience and foster closer partnerships with local contract manufacturing organizations. For organizations that embed these strategies proactively, the net effect may be an enhancement of operational flexibility and a competitive edge in an environment shaped by evolving trade policies.

Segmenting Microbiome Therapeutics for Strategic Advantage

A nuanced examination of the microbiome therapeutics market reveals distinct patterns when disaggregated by product category, therapeutic focus, formulation type, raw material origin, end-use setting, and distribution channels. Within the product spectrum, fecal microbiota transplantation remains a cornerstone of clinical inquiry, while live-biotherapeutics and defined microbiome ecosystem therapies are gaining traction for their precision targeting. Traditional probiotic and prebiotic compounds continue to serve as accessible entry points for gut health interventions, and dedicated microbiome drugs are emerging to address complex disease pathways with molecular specificity.

Across therapeutic areas, initiatives span autoimmune diseases, oncology, gastrointestinal disorders, infectious diseases, metabolic syndromes, and neurological conditions, each leveraging unique microbial modulation strategies. Oral formulations dominate early adoption due to established manufacturing capabilities and patient familiarity, but topical applications are carving out niche opportunities in dermatological and wound-healing contexts. The source of microbial matter further distinguishes offerings, with human-derived strains prized for safety and efficacy, animal microbiomes contributing novel bioactives, and environmental isolates opening unconventional avenues for discovery.

Institutions and clinical environments serve as primary end-use settings, with academic centers driving exploratory research and hospitals and clinics validating clinical protocols. Finally, distribution structures bifurcate between offline channels-including hospital and retail pharmacies-and burgeoning online pharmacies, which offer streamlined procurement options for both clinicians and consumers. Integrating these segmentation insights equips stakeholders to tailor product development, clinical trial design, and go-to-market strategies for maximum impact.

Regional Dynamics Shaping Microbiome Therapeutics Adoption

Geographic markets exhibit differing maturity levels, regulatory landscapes, and investment climates that shape the trajectory of microbiome therapeutics adoption. In the Americas, robust venture capital funding, an established biotech ecosystem, and progressive regulatory pathways have fostered rapid innovation cycles. This region serves as a bellwether for clinical validation and commercialization strategies, and it often hosts pivotal trials that set global precedents.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks, healthcare infrastructures, and market dynamics. While the European Union has begun harmonizing guidelines for microbiome interventions, pockets of the Middle East and Africa demonstrate divergent levels of research funding and clinical capacity. Nevertheless, collaborative pan-regional initiatives and cross-border partnerships are progressively aligning standards and unlocking new patient populations.

Asia-Pacific is experiencing accelerated growth driven by supportive government policies, expanding manufacturing capabilities, and rising prevalence of target indications. Nations across the region are investing heavily in life sciences infrastructure, cultivating domestic biotech champions, and forging international research alliances. This confluence of resources and expertise positions Asia-Pacific as a critical accelerator for next-generation microbiome therapeutics.

Competitive Landscape and Leading Players in Microbiome Therapeutics

The competitive landscape of microbiome therapeutics encompasses a diverse array of emerging biotech innovators, established pharmaceutical companies, and specialty contract research organizations. Several early-stage companies have distinguished themselves through novel platform technologies that enable high-throughput screening of microbial consortia and advanced biomarker-driven patient stratification tools. These capabilities facilitate rapid candidate selection and more efficient clinical trial design.

Meanwhile, leading pharmaceutical corporations are leveraging acquisitions and strategic alliances to integrate microbiome expertise into existing R&D pipelines. Partnerships with academic centers and clinical networks further augment their access to specialized patient cohorts and translational research infrastructure. Contract manufacturing and development organizations are also scaling capabilities to support bespoke fermentation processes, stringent product characterization, and regulatory compliance, thereby smoothing the path to market for both emerging and established players.

Strategic Recommendations to Navigate Microbiome Market Complexity

To capitalize on the evolving microbiome therapeutics market, industry leaders should prioritize integrated R&D frameworks that align scientific discovery with clinical development milestones. Establishing cross-disciplinary teams that combine microbiologists, immunologists, data scientists, and regulatory experts will accelerate target identification and mitigate technical risks. Strategic partnerships with contract research and manufacturing organizations can further enhance throughput while conserving internal resources.

In parallel, companies must proactively engage with regulatory authorities to shape adaptive guidelines and address emerging quality control considerations. Early dialogue around trial design, endpoint validation, and safety monitoring will foster a smoother approval process. Finally, adopting a dynamic supply chain strategy that incorporates both domestic and international sourcing options will safeguard against tariff fluctuations and logistical disruptions, ensuring consistent product availability as the market continues to expand.

Robust Methodology Underpinning the Microbiome Analysis

This analysis draws upon a comprehensive research methodology that combines primary and secondary data sources. Expert interviews with industry leaders, including senior scientists, clinical investigators, and manufacturing specialists, provided qualitative insights into technological trends, regulatory developments, and strategic priorities. Concurrently, a systematic review of peer-reviewed literature, patent filings, conference proceedings, and public financial disclosures informed the evaluation of competitive dynamics and product pipelines.

Data triangulation techniques were applied to reconcile potential discrepancies between public and proprietary information, ensuring a robust and balanced perspective. Inclusion criteria for company profiles and clinical programs emphasized relevance to core microbiome modalities and therapeutic areas, while exclusion criteria filtered out peripheral applications. Stakeholder validation sessions were conducted to refine interpretations and confirm the practical applicability of strategic recommendations.

Connecting Insights to Future Directions in Microbiome Therapy

The insights presented here outline the critical drivers, challenges, and opportunities that define the current microbiome therapeutics environment. Technological innovations and regulatory alignment are converging to create a more predictable pathway to market, while evolving trade policies underscore the need for resilient supply chain strategies. Segmentation analysis reveals targeted avenues for product differentiation, and regional dynamics highlight priority markets for investment and collaboration.

As the field progresses from exploratory research to clinical validation and commercial rollout, stakeholders equipped with granular market intelligence will be best positioned to outpace competitors and capture emerging value pools. Continuous monitoring of scientific breakthroughs, regulatory shifts, and competitive moves will be essential to sustain momentum and adapt strategic plans in real time.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Products
    • Fecal Microbiota Transplantation
    • Live-Biotherapeutics
    • Microbiome Drugs
    • Microbiome Ecosystem Therapies
    • Probiotics & Prebiotics
  • Therapeutic Area
    • Autoimmune Diseases
    • Cancer
    • Gastrointestinal Disorders
    • Infectious Diseases
    • Metabolic Disorders
    • Neurological Disorders
  • Formulation
    • Oral
    • Topical
  • Source
    • Animal Microbiome
    • Environmental Microbiome
    • Human Microbiome
  • End-use
    • Academic & Research Institutions
    • Hospitals & Clinics
  • Distribution Channel
    • Offline
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring B.V.
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Microbiome Therapeutics Market, by Products
8.1. Introduction
8.2. Fecal Microbiota Transplantation
8.3. Live-Biotherapeutics
8.4. Microbiome Drugs
8.5. Microbiome Ecosystem Therapies
8.6. Probiotics & Prebiotics
9. Microbiome Therapeutics Market, by Therapeutic Area
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cancer
9.4. Gastrointestinal Disorders
9.5. Infectious Diseases
9.6. Metabolic Disorders
9.7. Neurological Disorders
10. Microbiome Therapeutics Market, by Formulation
10.1. Introduction
10.2. Oral
10.3. Topical
11. Microbiome Therapeutics Market, by Source
11.1. Introduction
11.2. Animal Microbiome
11.3. Environmental Microbiome
11.4. Human Microbiome
12. Microbiome Therapeutics Market, by End-use
12.1. Introduction
12.2. Academic & Research Institutions
12.3. Hospitals & Clinics
13. Microbiome Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.2.1. Hospital Pharmacies
13.2.2. Retail Pharmacies
13.3. Online Pharmacies
14. Americas Microbiome Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Microbiome Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Microbiome Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Alveolus Bio, Inc. by ResBiotic
17.3.2. AOBiome LLC
17.3.3. Assembly Biosciences, Inc.
17.3.4. Axial Therapeutics, Inc.
17.3.5. BioGaia AB
17.3.6. BiomeBank
17.3.7. EnteroBiotix Ltd
17.3.8. Enterome SA
17.3.9. Ferring B.V.
17.3.10. Intralytix, Inc.
17.3.11. Kanvas Biosciences
17.3.12. Locus Biosciences, Inc.
17.3.13. MaaT Pharma SA
17.3.14. Microba Life Sciences Limited
17.3.15. Microbiotica Ltd.
17.3.16. MRM Health NV
17.3.17. NuBiyota
17.3.18. Osel, Inc.
17.3.19. Pendulum Therapeutics
17.3.20. PharmaBiome AG
17.3.21. Pylum Biosciences
17.3.22. Seres Therapeutics, Inc.
17.3.23. Servatus Limited
17.3.24. Siolta Therapeutics
17.3.25. Theriva Biologics, Inc.
17.3.26. Vedanta Biosciences, Inc.
17.3.27. Viome Life Sciences, Inc. by BlueDot LLC
17.3.28. Xbiome Co. Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MICROBIOME THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. MICROBIOME THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. MICROBIOME THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MICROBIOME THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY LIVE-BIOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY MICROBIOME ECOSYSTEM THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY PROBIOTICS & PREBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ANIMAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ENVIRONMENTAL MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HUMAN MICROBIOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MICROBIOME THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES MICROBIOME THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 52. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 53. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 55. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 56. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 60. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 96. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. GERMANY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 102. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 103. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 104. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 105. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 106. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. FRANCE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 115. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 116. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 117. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 118. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 119. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 120. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. ITALY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 123. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 124. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SPAIN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 151. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 152. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 153. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. DENMARK MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 164. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 165. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 166. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 168. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 169. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. QATAR MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 173. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 174. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 175. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 176. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. FINLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 194. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 197. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. EGYPT MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 200. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 201. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 202. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 203. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 204. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. TURKEY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 215. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 217. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 218. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. NORWAY MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 220. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 221. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 222. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 223. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 224. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 225. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. POLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 242. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 243. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 244. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 245. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 246. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 247. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. CHINA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 249. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 250. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 251. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 252. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 253. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 254. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. INDIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 258. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 259. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 261. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. JAPAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 284. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 285. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 286. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 287. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 289. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. THAILAND MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 319. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 320. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 321. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 322. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 323. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN MICROBIOME THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
TABLE 326. MICROBIOME THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 327. MICROBIOME THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Microbiome Therapeutics market report include:
  • Alveolus Bio, Inc. by ResBiotic
  • AOBiome LLC
  • Assembly Biosciences, Inc.
  • Axial Therapeutics, Inc.
  • BioGaia AB
  • BiomeBank
  • EnteroBiotix Ltd
  • Enterome SA
  • Ferring B.V.
  • Intralytix, Inc.
  • Kanvas Biosciences
  • Locus Biosciences, Inc.
  • MaaT Pharma SA
  • Microba Life Sciences Limited
  • Microbiotica Ltd.
  • MRM Health NV
  • NuBiyota
  • Osel, Inc.
  • Pendulum Therapeutics
  • PharmaBiome AG
  • Pylum Biosciences
  • Seres Therapeutics, Inc.
  • Servatus Limited
  • Siolta Therapeutics
  • Theriva Biologics, Inc.
  • Vedanta Biosciences, Inc.
  • Viome Life Sciences, Inc. by BlueDot LLC
  • Xbiome Co. Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.27 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.54 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Human Microbiome Market by Product Type, Application, Indication, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Human Microbiome Market by Product Type, Application, Indication, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Microbiome Diagnostics Market by Technology, Diagnostic Application, Sample Type, Indication, End User, Service Type, Component - Global Forecast to 2030 - Product Image

Microbiome Diagnostics Market by Technology, Diagnostic Application, Sample Type, Indication, End User, Service Type, Component - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Live Biotherapeutic Products and Microbiome CDMO Market Size, Share & Trends Analysis Report by Application (C.Difficle, Crohns Disease, IBS, Diabetes, Others), Region (MEA, Asia Pacific), and Segment Forecasts, 2024-2030 - Product Image

Live Biotherapeutic Products and Microbiome CDMO Market Size, Share & Trends Analysis Report by Application (C.Difficle, Crohns Disease, IBS, Diabetes, Others), Region (MEA, Asia Pacific), and Segment Forecasts, 2024-2030

  • Report
  • 137 Pages
  • Global
From
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-Term Care) - Global Forecast to 2030 - Product Image

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-Term Care) - Global Forecast to 2030

  • Report
  • 291 Pages
  • Global
From
Microbiome Sample Preparation Technology Market Size, Share & Trends Analysis Report by Product (Instruments, Consumables), Workflow, Application, Disease, End-use, Region, and Segment Forecasts, 2025-2030 - Product Image

Microbiome Sample Preparation Technology Market Size, Share & Trends Analysis Report by Product (Instruments, Consumables), Workflow, Application, Disease, End-use, Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From

About the Microbiome Market

The Microbiome market is a subset of the biotechnology industry that focuses on the study of microbial communities and their interactions with the environment. It is a rapidly growing field, with research and development activities focusing on the development of new products and services that can be used to improve human health and the environment. Microbiome-based products and services are used in a variety of industries, including pharmaceuticals, food and beverage, agriculture, and cosmetics. The Microbiome market is driven by the increasing demand for personalized medicine, as well as the need for more efficient and cost-effective treatments for various diseases. Additionally, the development of new technologies, such as next-generation sequencing and metagenomics, has enabled researchers to better understand the composition and function of microbial communities. Companies in the Microbiome market include Second Genome, uBiome, Seres Therapeutics, and Enterome Bioscience. These companies are focused on developing products and services that can be used to improve human health and the environment. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.